|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 96 No. 1 (July 1), 2000:
pp. 355-357
BRIEF REPORT
Molecular monitoring of minimal residual disease in patients
in long-term complete remission after allogeneic stem cell
transplantation for multiple myeloma
Michele Cavo,
Carolina Terragna,
Giovanni Martinelli,
Sonia Ronconi,
Elena Zamagni,
Patrizia Tosi,
Roberto M. Lemoli,
Monica Benni,
Giorgio Pagliani,
Giuseppe Bandini, and
Sante Tura
From the Institute of Hematology and Medical Oncology
"Seràgnoli," University of Bologna, Bologna, Italy.
In the present study, we used a polymerase chain reaction-based
(PCR-based) strategy to retrospectively analyze the presence of
residual myeloma cells in serial posttransplant bone marrow samples
obtained from 13 patients in remission after allogeneic hemopoietic
stem cell transplantation (allo SCT). For this purpose, patient-specific primers were generated from complementarity
determining regions 2 and 3 of the rearranged IgH gene.
The level of sensitivity of the PCR-based assay ranged from 1 in
105 to 1 in 106 normal marrow cells. Following
transplantation, 9 of 12 patients who attained stringently
defined complete remission (CR) remained persistently
PCR for a median of 36 months, and 4 of the patients
remained PCR up to the latest analysis, which was
performed at 48, 72, 72, and 120 months, respectively, after allo SCT.
None of the patients in the PCR subgroup experienced a
disease relapse, and only 1 of 4 PCR+ patients
experienced a relapse. It is concluded that allo SCT has the potential
ability to induce sustained serological and molecular CR in selected
patients with multiple myeloma.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. J. Lahuerta, M. V. Mateos, J. Martinez-Lopez, L. Rosinol, A. Sureda, J. de la Rubia, J. Garcia-Larana, R. Martinez-Martinez, M. T. Hernandez-Garcia, D. Carrera, et al.
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
J. Clin. Oncol.,
December 10, 2008;
26(35):
5775 - 5782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, J. Epstein, and J. D. Shaughnessy Jr
Going with the flow, and beyond, in myeloma
Blood,
November 15, 2008;
112(10):
3917 - 3918.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Paiva, M.-B. Vidriales, J. Cervero, G. Mateo, J. J. Perez, M. A. Montalban, A. Sureda, L. Montejano, N. C. Gutierrez, A. G. de Coca, et al.
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Blood,
November 15, 2008;
112(10):
4017 - 4023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol.,
January 20, 2008;
26(3):
480 - 492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cavo
New insights into the knowledge of graft-versus-myeloma
Blood,
January 15, 2004;
103(2):
371 - 372.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Corradini, M. Cavo, H. Lokhorst, G. Martinelli, C. Terragna, I. Majolino, P. Valagussa, M. Boccadoro, D. Samson, A. Bacigalupo, et al.
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
Blood,
September 1, 2003;
102(5):
1927 - 1929.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Badros, B. Barlogie, E. Siegel, M. Cottler-Fox, M. Zangari, A. Fassas, C. Morris, E. Anaissie, F. Van Rhee, and G. Tricot
Improved Outcome of Allogeneic Transplantation in High-Risk Multiple Myeloma Patients After Nonmyeloablative Conditioning
J. Clin. Oncol.,
March 1, 2002;
20(5):
1295 - 1303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cutler and J. H. Antin
Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review
Stem Cells,
February 1, 2001;
19(2):
108 - 117.
[Abstract]
[Full Text]
|
|
|
|
|
